Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC - Trauner, Michael; Bowlus, Christopher L.; Gulamhusein, Aliya; Hameed, Bilal; Caldwell, Stephen H.; Shiffman, Mitchell L.; Landis, Charles; Muir, Andrew J.; Billin, Andrew; Xu, Jun; Liu, Xiangyu; Lu, Xiaomin; et al. (Clinical gastroenterology and hepatology, 2023)
Keywords: Adult; Alkaline Phosphatase; Bile Acids and Salts; Biomarkers; Cholangitis, Sclerosing - drug therapy; Cholestasis; Farnesoid X Receptor; Female; gamma-Glutamyltransferase; Gastroenterology and Hepatology; Humans; Large Duct PSC; Liver; Male; Primary Sclerosing Cholangitis; UDCA; Ursodeoxycholic Acid - therapeutic use; FXR; PSC; AST; TIMP-1; AE; Farnesoid X Receptor; ALP; Large Duct PSC; ALT; OLE; UDCA; IQR; CYP7A1; CK18; C4; GGT; FGF19; SAE; ULN; Primary Sclerosing Cholangitis; PIII-NP; Cholestasis; ELF; BA; aspartate aminotransaminase; Enhanced Liver Fibrosis; interquartile range; 7α-hydroxy-4-cholesten-3-one; gamma-glutamyl transferase; ursodeoxycholic acid; serious adverse event; alkaline phosphatase; fibroblast growth factor 19; cholesterol 7ɑ-hydroxylase; bile acid; adverse event; upper limit of normal; cytokeratin 18; open-label extension; alanine aminotransaminase; tissue inhibitor of metalloproteinase-1; procollagen III N-terminal peptide